Psychedelic Microdosing: Prevalence and Subjective Effects
Open accessAbstract
Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule – a practice known as psychedelic microdosing – is becoming increasingly popular among young adults due to its purported ability to reduce symptoms of depression and anxiety while improving cognitive function and promoting social interaction. Using an anonymous online survey, we collected data from 2347 people to 1) assess the prevalence of psychedelic microdosing and characterize the demographics of microdosers, 2) determine whether microdosers associate the practice with changes in mood, cognitive function, social interaction, or physiology, and 3) investigate frequent motives for discontinuing the practice. Fifty-nine percent of respondents (NT = 2183) reported familiarity with the concept of psychedelic microdosing, with 17% (383 respondents, NT = 2200) having engaged in this practice. Microdosers attributed psychedelic microdosing with improving their mood, decreasing their anxiety, and enhancing their memory, attention, and sociability. The most frequently cited reasons for quitting microdosing (NT = 243) were the risks associated with taking an illegal substance (24.28%) and the difficulty of obtaining psychedelic compounds (22.63%). Overall, our findings suggest that psychedelic microdosing is relatively common and is subjectively associated with a broad spectrum of socio-affective, cognitive, and physical outcomes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Therapeutic benefit of low doses of psychedelics remains to be demonstrated in a well-controlled clinical study.
“therapeutic benefit of low doses of psychedelics remains to be demonstrated in a well-controlled clinical study”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [247]
Data on human psychedelic microdosing are equivocal.
“the data on human psychedelic microdosing are equivocal”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [247]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006 · see citing works
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2× · see citing works
“Current therapeutics for depression are slow-acting, taking several weeks before demonstrating efficacy, and approximately 1/3 of patients will not respond to them (Rush et al. 2006).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1× · see citing works
“Specifically, psilocybin has been shown to ameliorate end of life anxiety in terminal cancer patients (Griffiths et al. 2016), 3,4-methylenedioxymethamphetamine (MDMA) has produced positive effects in patients suffering from PTSD (Dunlap, Andrews, and Olson 2018), and the DMT-containing tisane…”
BackgroundCost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723 · see citing works
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · see citing works
Self-citationCost of disorders of the brain in Europe
Andlin‐Sobocki, P., Jönsson, B., Wïttchen, H., & Olesen, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01202.x · Cited by 1,139 · see citing works
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic
Ressler, K. J., & Mayberg, H. S. (2007) · Nature Neuroscience · doi:10.1038/nn1944 · Cited by 1,007 · see citing works
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · see citing works
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · see citing works
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587 · see citing works
Assessing the economic costs of serious mental illness
Insel, T. R. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030366 · Cited by 487 · see citing works
Kessler, R. C., Heeringa, S., Lakoma, M. D., Petukhova, M., Rupp, A. E., Schoenbaum, M., Wang, P. S., & Zaslavsky, A. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08010126 · Cited by 486 · see citing works
Phillips, C. (2017) · Neural Plasticity · doi:10.1155/2017/7260130 · Cited by 456 · see citing works
Psychedelics as Medicines: An Emerging New Paradigm
Nichols, D. E., Johnson, M., & Nichols, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 373 · see citing works
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313 · see citing works
Cure therapeutics and strategic prevention: raising the bar for mental health research
Insel, T. R., & Scolnick, E. M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001777 · Cited by 313 · see citing works
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306 · see citing works
The burden of brain diseases in Europe
Olesen, J., & Leonardi, M. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00682.x · Cited by 269 · see citing works
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · see citing works
Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior
Brachman, R. A., McGowan, J. C., Perusini, J. N., Lim, S. C., Pham, T. H., Faye, C., Gardier, A. M., Mendez‐David, I., David, D. J. P., Hen, R., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.022 · Cited by 258 · see citing works
Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics
Olson, D. E. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518800508 · Cited by 257 · see citing works
Self-citationNovel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239 · see citing works
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235 · cited 1× · see citing works
“…experiencing a decrease in depressive symptoms following psychedelic microdosing, mirroring other work demonstrating that microdosing decreases negative emotionality and improves mood (Anderson et al. 2019a; Anderson et al. 2019b; Fadiman and Korb 2019; Johnstad 2018; Polito and Stevenson 2018).”
BackgroundAbnormal mTOR Activation in Autism
Winden, K. D., Ebrahimi‐Fakhari, D., & Şahin, M. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061747 · Cited by 222 · see citing works
Hert, M. D., & Peuskens, J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01388.x · Cited by 182 · see citing works
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchar, M., Sjoerds, Z., & Hommel, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5049-7 · Cited by 177 · see citing works
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174 · see citing works
Effects of <i>N</i>,<i>N</i>-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171 · see citing works
Self-citationCameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168 · see citing works
Self-citationYanakieva, S., Polychroni, N., Family, N., Williams, L. T. J., Luke, D. P., & Terhune, D. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5119-x · Cited by 167 · see citing works
Activation of mTOR: a culprit of Alzheimer&rsquo;s disease?
Cai, Z., Zhou, Y., Xiao, M., Yan, L.-J., & He, W. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75717 · Cited by 161 · see citing works
Powerful substances in tiny amounts: An interview study of psychedelic microdosing
Johnstad, P. G. (2018) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072517753339 · Cited by 155 · cited 2× · see citing works
“…experiencing a decrease in depressive symptoms following psychedelic microdosing, mirroring other work demonstrating that microdosing decreases negative emotionality and improves mood (Anderson et al. 2019a; Anderson et al. 2019b; Fadiman and Korb 2019; Johnstad 2018; Polito and Stevenson 2018).”
BackgroundPsychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155 · cited 1× · see citing works
“…have shown promise as experimental therapeutics in the clinic for treating depression, anxiety, and substance use disorder (Cameron and Olson 2018b; Carhart-Harris and Goodwin 2017; Dos Santos et al. 2016; Kyzar et al. 2017; Mithoefer, Grob, and Brewerton 2016; Nichols, Johnson, and Nichols 2017).”
Background3,4-Methylenedioxymethamphetamine facilitates fear extinction learning
Young, M. B., Andero, R., Ressler, K. J., & Howell, L. L. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.138 · Cited by 141 · see citing works
Motives and Side-Effects of Microdosing With Psychedelics Among Users
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz029 · Cited by 126 · see citing works
Might microdosing psychedelics be safe and beneficial? An initial exploration
Fadiman, J., & Korb, S. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1593561 · Cited by 125 · see citing works
Psychedelic microdosing benefits and challenges: an empirical codebook
Anderson, T., Petranker, R., Christopher, A., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0308-4 · Cited by 124 · see citing works
Maier, L. J., Ferris, J., & WINSTOCK, A. R. (2018) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2018.05.009 · Cited by 120 · see citing works
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 117 · see citing works
Self-citationIs it time to revisit the role of psychedelic drugs in enhancing human creativity?
Sessa, B. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091597 · Cited by 115 · see citing works
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106 · see citing works
Self-citationProphylactic Ketamine Attenuates Learned Fear
McGowan, J. C., LaGamma, C. T., Lim, S. C., Tsitsiklis, M., Neria, Y., Brachman, R. A., & Denny, C. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.19 · Cited by 90 · see citing works
Revitalizing Psychiatric Therapeutics
Hyman, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.181 · Cited by 89 · see citing works
Amat, J., Dolzani, S. D., Tilden, S. G., Christianson, J. P., Kubala, K. H., Bartholomay, K. L., Sperr, K., Ciancio, N., Watkins, L. R., & Maier, S. F. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3114-15.2016 · Cited by 79 · see citing works
Narrative identity, rationality, and microdosing classic psychedelics
Webb, M. E., Copes, H., & Hendricks, P. S. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.04.013 · Cited by 75 · see citing works
In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N,N-dimethyltryptamine in the rat
Sitaram, B. R., Lockett, L., Talomsin, R., Blackman, G. L., & McLeod, W. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90118-3 · Cited by 74 · see citing works
Horsley, R. R., Páleníček, T., Kolin, J., & Valeš, K. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000394 · Cited by 52 · see citing works
Global Drug Survey 2018 key findings report
WINSTOCK, A. R., Barratt, M. J., Maier, L. J., & Ferris, J. (2018) · Cited by 17 · see citing works
A Systematic Study of Microdosing PsychedelicsPreprint
Polito, V., & Stevenson, R. J. (2018) · doi:10.31234/osf.io/cw9qs · Cited by 13 · see citing works
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Cameron LP, Benson CJ, DeFelice BC, Fiehn O, and Olson DE. 2019 Chronic, Intermittent, Low Doses of N,N-Dimethyltryptamine Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chemical Neuroscience 10: 3261– 3270. 30829033 PMC6639775
- Fadiman J 2011 The Psychedelic Explorer’s Guide. Rochester, VT: Park Street Press.
Cited by
Sorted by citations
The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00192 · Cited by 329 · see citing works
Self-citationPharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221 · see citing works
Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168 · see citing works
Self-citationPsychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166 · see citing works
Self-citationPositive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81446-7 · Cited by 145 · see citing works
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02039-0 · Cited by 148 · see citing works
Polito, V., & Liknaitzky, P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104706 · Cited by 113 · see citing works
Trends in LSD use among US adults: 2015–2018
Yockey, R. A., Vidourek, R. A., & King, K. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108071 · Cited by 111 · see citing works
The acute effects of classic psychedelics on memory in humans
Healy, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05756-w · Cited by 95 · see citing works
Livne, O., Shmulewitz, D., Walsh, C. A., & Hasin, D. S. (2022) · Addiction · doi:10.1111/add.15987 · Cited by 92 · see citing works
Rootman, J. M., Kryskow, P., Harvey, K., Stamets, P. E., Santos-Brault, E., Kuypers, K. P. C., Polito, V., Bourzat, F., & Walsh, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-01811-4 · Cited by 79 · see citing works
Marschall, J., Fejer, G., Lempe, P., Prochazkova, L., Kuchar, M., Hajkova, K., & van Elk, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211050556 · Cited by 72 · see citing works
Murphy, R. J., Sumner, R. L., Evans, W., Ponton, R., Ram, S., Godfrey, K., Forsyth, A., Cavadino, A., Naga, V. K., Smith, T., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.03.013 · Cited by 67 · see citing works
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58 · see citing works
Oña, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 58 · see citing works
Rootman, J. M., Kiraga, M. K., Kryskow, P., Harvey, K., Stamets, P. E., Santos-Brault, E., Kuypers, K. P. C., & Walsh, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-14512-3 · Cited by 57 · see citing works
Devenot, N., Conner, T., & Doyle, R. (2022) · Anthropology of Consciousness · doi:10.1111/anoc.12154 · Cited by 52 · see citing works
Toxicology and Analysis of Psychoactive Tryptamines
Malaca, S., Faro, A. F. L., Tamborra, A., Pichini, S., Busardò, F. P., & Huestis, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239279 · Cited by 47 · see citing works
Wießner, I., Olivieri, R., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., de Araújo, D. B., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.114 · Cited by 44 · see citing works
Rouaud, A., Calder, A. E., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231225609 · Cited by 44 · see citing works
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190865 · Cited by 41 · see citing works
Nootropic effects of LSD: Behavioral, molecular and computational evidence
Ornelas, I. M., da Silva, F. A. C., Wießner, I., Marcos, E., de Araújo, D. B., Goto‐Silva, L., Nascimento, J. M., Silva, S. R. B., Costa, M., Falchi-Carvalho, M., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114148 · Cited by 35 · see citing works
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019
Walsh, C. A., Livne, O., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100454 · Cited by 36 · see citing works
Murray, C. H., Frohlich, J., Haggarty, C. J., Tare, I., Lee, R., & de Wit, H. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01809-2 · Cited by 36 · see citing works
Liechti, M. E., & Holze, F. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_270 · Cited by 35 · see citing works
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 32 · see citing works
Pearson, C., Siegel, J. S., & Gold, J. A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120096 · Cited by 31 · see citing works
Molecular targets of psychedelic‐induced plasticity
Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 30 · see citing works
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29 · see citing works
Use of Lysergic Acid Diethylamide by Major Depression Status
Walsh, C. A., Gorfinkel, L., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.3867 · Cited by 26 · see citing works
Murphy, R. J., Sumner, R. L., Evans, W., Menkes, D. B., Lambrecht, I., Ponton, R., Sundram, F., Hoeh, N. R., Ram, S., Reynolds, L., et al. (2021) · Trials · doi:10.1186/s13063-021-05243-3 · Cited by 23 · see citing works
Set and setting in microdosing: an oft-overlooked principle
Hartogsohn, I., & Petranker, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06249-8 · Cited by 22 · see citing works
Barnett, B. S., Anand, A., Dewey, E. N., Smith, D. T., Nayak, S. M., Bruckman, D., & Weleff, J. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0027 · Cited by 22 · see citing works
Donegan, C. J., Daldegan‐Bueno, D., Sumner, R. L., Menkes, D. B., Evans, W., Hoeh, N. R., Sundram, F., Reynolds, L., Ponton, R., Cavadino, A., et al. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01399-8 · Cited by 21 · see citing works
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US
Yang, K. H., Satybaldiyeva, N., Allen, M. R., Ayers, J. W., & Leas, E. C. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.1653 · Cited by 19 · see citing works
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults
Mueller, L., de Jesus, J. S., Schmid, Y., Müller, F., Becker, A., Klaiber, A., Straumann, I., Luethi, D., Haijen, E. C. H. M., Hurks, P. P. M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0044 · Cited by 20 · see citing works
Natural language signatures of psilocybin microdosing
Sanz, C., Cavanna, F., Muller, S. L., de la Fuente, L., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Carrillo, F., García, A. M., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06170-0 · Cited by 19 · see citing works
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research
Polito, V., & Liknaitzky, P. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241254831 · Cited by 19 · see citing works
Campanale, A., Inserra, A., & Comai, S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111058 · Cited by 18 · see citing works
Inserra, A., Piot, A., Gregorio, D. D., & Gobbi, G. (2023) · CNS Drugs · doi:10.1007/s40263-023-01008-5 · Cited by 17 · see citing works
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
Liokaftos, D. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.103099 · Cited by 17 · see citing works
Pilozzi, A. R., Foster, S. L., Mischoulon, D., D, M. F. M., & Huang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512513 · Cited by 15 · see citing works
Bis(4-hydroxy-N-isopropyl-N-methyltryptammonium) fumarate: a new crystalline form of miprocin
Chadeayne, A. R., Pham, D. N. K., Golen, J. A., & Manke, D. R. (2020) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989020002923 · Cited by 15 · see citing works
van den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 14 · see citing works
Daldegan‐Bueno, D., Donegan, C. J., Forsyth, A., Sumner, R. L., Murphy, R. J., Menkes, D. B., Evans, W., Hoeh, N. R., Sundram, F., Reynolds, L., et al. (2024) · Trials · doi:10.1186/s13063-024-08384-3 · Cited by 14 · see citing works
Strauss, D., Ghosh, S. B., Murray, Z., & Gryzenhout, M. (2022) · 3 Biotech · doi:10.1007/s13205-022-03355-4 · Cited by 13 · see citing works
Psychedelic-assisted psychotherapy for depression: How dire is the need? How could we do it?
Earleywine, M., & Leo, J. A. D. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00134 · Cited by 13 · see citing works
Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.8 · Cited by 12 · see citing works
Less is more? A review of psilocybin microdosing
Savides, I. A., & Outhoff, K. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278769 · Cited by 12 · see citing works
Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice
Pędzich, B. D., Medrano, M., Buckinx, A., Smolders, I. J., & Bundel, D. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315284 · Cited by 11 · see citing works
Syed, O. A., Petranker, R., Fewster, E. C., Sobolenko, V., Beidas, Z., Husain, M. I., Lake, S., & Lucas, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424284 · Cited by 11 · see citing works
Grinschgl, S., Ninaus, M., Wood, G. M. D. O., & Neubauer, A. C. (2025) · Physics of Life Reviews · doi:10.1016/j.plrev.2025.05.002 · Cited by 10 · see citing works
Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series
Gukasyan, N., & Narayan, S. K. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2157350 · Cited by 10 · see citing works
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 10 · see citing works
Modzelewski, S., Stankiewicz, A., Waszkiewicz, N., & Łukasiewicz, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110402 · Cited by 9 · see citing works
Smith, F. N., Neill, J. C., & Wainwright, V. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221124117 · Cited by 9 · see citing works
Psychedelic Microdosing among Young Adults from Southern California
Harlow, A. F., Hendricks, P. S., Leventhal, A. M., & Barrington‐Trimis, J. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2313684 · Cited by 7 · see citing works
Kinderlehrer, D. A. (2023) · International Medical Case Reports Journal · doi:10.2147/imcrj.s395342 · Cited by 7 · see citing works
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470657 · Cited by 7 · see citing works
Between enhancement and risk: A critical review of psychedelic microdosing
Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2025.102129 · Cited by 6 · see citing works
Colognesi, M., Gabbia, D., Signor, A., Sarill, M., Centofanti, L., Rinaldi, A., Cascione, L., Nunziata, S., Banzato, M., Mattarei, A., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108080 · Cited by 7 · see citing works
Anderson, K., Elf, P., & Isham, A. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104571 · Cited by 6 · see citing works
Asking questions of psychedelic microdosing
Cameron, L. P. (2021) · eLife · doi:10.7554/elife.66920 · Cited by 6 · see citing works
Self-citationCan the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?
Kit, A., Conway, K., Makarowski, S., O'Regan, G., Allen, J., Shultz, S. R., Bodnar, T. S., & Christie, B. R. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100732 · Cited by 5 · see citing works
Psychedelic Drug Microdosing Practices: A Qualitative Online Exploration
Miller, E., Bojovic, V., Maddren, O., Rao, P., Adesina, D., Petrenko, A., & Ponton, R. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2304554 · Cited by 5 · see citing works
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5 · see citing works
Donegan, C. J., Daldegan‐Bueno, D., Noorani, T. N., Sumner, R. L., Forsyth, A., Evans, W., Smith, T., Hoeh, N. R., Sundram, F., Menkes, D. B., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110670 · Cited by 4 · see citing works
Fandiño, O. E., Hutton, A. R. J., Zhang, C., Abbate, M. T. A., Naser, Y. A., Li, Y., Paredes, A. J., & Donnelly, R. F. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114603 · Cited by 4 · see citing works
Barker, S. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111259 · Cited by 4 · see citing works
Hernández‐Álvarez, E., Borkel, L. F., Rojas‐Hernández, J., Hernández, D. J. Q., García‐Serrano, I., Fernández‐Borkel, T., Zumbado, M. L., & Henríquez‐Hernández, L. A. (2025) · Veterinary Medicine and Science · doi:10.1002/vms3.70486 · Cited by 4 · see citing works
Psychedelics for substance use disorders: are women being addressed? A scoping review
Nigri, A. W., de Arruda, I. F., Maia, C. G. F., Tófoli, L. F., & Carezzato, F. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104960 · Cited by 3 · see citing works
Beyond prohibition: A public health analysis of naturalistic psychedelic use
Haden, M., Paschall, S. A., & Woods, B. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00450 · Cited by 3 · see citing works
A long trip into the universe: Psychedelics and space travel
Lerer, L. B., & Varia, J. C. (2022) · Frontiers in Space Technologies · doi:10.3389/frspt.2022.899159 · Cited by 3 · see citing works
Microdosing psychedelics has no impact on cognitive function in naturalistic settings
Dinkelacker, J., & Pop, I. (2023) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2023.14.00738 · Cited by 3 · see citing works
Baxter, L., Puljević, C., Piatkowski, T. M., Ferris, J., Davies, E., Barratt, M. J., & WINSTOCK, A. R. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241254837 · Cited by 3 · see citing works
Cuttler, C., Stueber, A., Simone, J. J., & Mayo, L. M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2452226 · Cited by 3 · see citing works
Psychedelics and schizophrenia: A mystery in history
Haden, M., Woods, B., & Paschall, S. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00277 · Cited by 2 · see citing works
Psychedelics and cognitive function: A systematic review
Cardoso, C. G., & Viana, M. D. B. (2023) · Research Society and Development · doi:10.33448/rsd-v12i14.44436 · Cited by 2 · see citing works
Calleja‐Conde, J., Echeverry‐Alzate, V., Sanz-SanCristóbal, M., Alonso‐Gil, S., Giné, E., Bühler, K., López-Moreno, J. A., Perez-Castillo, A., & Morales-Garcia, J. A. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115822 · Cited by 2 · see citing works
Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)
Diab, H., & Malcolm, B. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1847366 · Cited by 2 · see citing works
Aghaei, A. M., Weleff, J., Martins, B. S., Ing, K., Fontenele, R., Barnett, B. S., Anand, A., & Nia, A. B. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00574-y · Cited by 2 · see citing works
Mann, J. D. (2022) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2022.2064268 · Cited by 2 · see citing works
Polito, V., & Liknaitzky, P. (2021) · doi:10.31234/osf.io/edhqz · Cited by 2 · see citing works
Is Microdosing a Placebo?Preprint
Polito, V., & Liknaitzky, P. (2023) · doi:10.31234/osf.io/3ykst · Cited by 2 · see citing works
Arnison, C., Egan, R., & Shaver, J. H. (2025) · Kōtuitui New Zealand Journal of Social Sciences Online · doi:10.1080/1177083x.2025.2467035 · Cited by 1 · see citing works
Meshkat, S., Fang, H., Sousa-Ho, R., Zeifman, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0039 · Cited by 1 · see citing works
Exploring the effects of microdosing on health behaviour change
Prochazkova, L., de Carvalho, L. L., Marrouch, N., Encantado, J., & Teixeira, P. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110688 · Cited by 1 · see citing works
Beidas, Z., Ragnhildstveit, A., Blackman, A., Anderson, T., Fewster, E. C., Syed, O. A., Sobolenko, V., Kanca, I. K., Jaglinska, M., Son, T., et al. (2026) · BJPsych Open · doi:10.1192/bjo.2025.10968 · Cited by 1 · see citing works
Hammel, R. L., Gulliver, B. J., Sukich, S. N., & Abraham, S. (2022) · International Journal of Science and Research Methodology · doi:10.25166/ijsrm/2022.20.3.2 · Cited by 1 · see citing works
Well-Being and the Outdoors: An Environmentalism Study Among a Religious Student Population
Pires-Gifford, L., Hoffmann, S., Arroyo, E., Jones, N., Waite, B., & Wright, R. R. (2022) · Psi Chi Journal of Psychological Research · doi:10.24839/2325-7342.jn27.3.185
Wright, R. R., Treadwell, K. R. H., & Hughes, J. L. (2022) · Psi Chi Journal of Psychological Research · doi:10.24839/2325-7342.jn27.3.223 · Cited by 1 · see citing works
Tendencias y experiencias del consumo de microdosis de hongos psilocibios en Colombia
Suárez, C., Quintero, S., & Gil, J. M. C. (2023) · Cultura y Droga · doi:10.17151/culdr.2023.28.35.7
Investigación sobre microdosificación con hongos psilocibios: un artículo de reflexión
Duque, L. (2023) · Cultura y Droga · doi:10.17151/culdr.2023.28.35.3
Ferreira, A. S. M., Martindale, S., & Luke, D. P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00368
Psilocybin Microdosing for Anxiety Relief in Young Adults: A Comparative Review of Emerging Evidence
Shabir, K. (2024) · Premier journal of science. · doi:10.70389/pjs.100036
Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.002
Gunten, M. V., Russell, T., Stirland, I., Parks, S., Jenkins, T. G., & Edwards, J. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.658958
Psychedelic agents for treatment-resistant depression
Gukasyan, N., & Griffiths, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00014-1
Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review
de Oliveira, A. L., de Oliveira, D. P., SANTOS, R. G. D., & Hallak, J. E. C. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111534
- Authors
- Cameron, L. P., Nazarian, A., & Olson, D. E.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Cameron, Lindsay P.
- Olson, David E.
- Venue
- Journal of Psychoactive Drugs
- Publisher
- Informa UK Limited
- Published
- 2020-01-23
- Volume
- 52
- Issue
- 2
- Pages
- 113-122
- ISSN
- 0279-1072 (ISSN-L)
- 2159-9777
- PMC
- PMC7282936
- OpenAlex
- W3002125030
- Cited by
- 110
- References
- 51
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 21 · 2023: 14 · 2022: 24 · 2021: 15 · 2020: 7 · 2019: 1
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Psychoactive Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- NIH Office of the Director (T32MH112507)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- psychedelic microdosing, prevalence, subjective effects, mood, anxiety, cognitive function, memory, sociability, young adults, illicit drug use
- MeSH terms
- Self-Management, Adolescent, Adult, Behavioral Symptoms, Cognition, Hallucinogens, Health Surveys, Humans, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
